Literature DB >> 29610520

Comment on: 'An international comparison of retinopathy of prematurity grading performance within the Benefits of Oxygen Saturation Targeting II trials'.

F R Burgess1, R Davies2, A O Mulvihill2, C L L Schmoll2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29610520      PMCID： PMC6043489          DOI： 10.1038/s41433-018-0083-6

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  4 in total

Review 1.  The International Classification of Retinopathy of Prematurity revisited.

Authors: 
Journal:  Arch Ophthalmol       Date:  2005-07

2.  Interexpert agreement of plus disease diagnosis in retinopathy of prematurity.

Authors:  Michael F Chiang; Lei Jiang; Rony Gelman; Yunling E Du; John T Flynn
Journal:  Arch Ophthalmol       Date:  2007-07

3.  Outcomes of Two Trials of Oxygen-Saturation Targets in Preterm Infants.

Authors:  William Tarnow-Mordi; Ben Stenson; Adrienne Kirby; Edmund Juszczak; Mark Donoghoe; Sanjeev Deshpande; Colin Morley; Andrew King; Lex W Doyle; Brian W Fleck; Peter G Davis; Henry L Halliday; Wendy Hague; Pamela Cairns; Brian A Darlow; Alistair R Fielder; Val Gebski; Neil Marlow; Karen Simmer; Win Tin; Alpana Ghadge; Cathy Williams; Anthony Keech; Stephen P Wardle; Zsuzsoka Kecskes; Martin Kluckow; Glen Gole; Nicholas Evans; Girvan Malcolm; Melissa Luig; Ian Wright; Jacqueline Stack; Kenneth Tan; Margo Pritchard; Peter H Gray; Scott Morris; Bevan Headley; Peter Dargaville; R John Simes; Peter Brocklehurst
Journal:  N Engl J Med       Date:  2016-02-10       Impact factor: 91.245

4.  An international comparison of retinopathy of prematurity grading performance within the Benefits of Oxygen Saturation Targeting II trials.

Authors:  B W Fleck; C Williams; E Juszczak; K Cocker; B J Stenson; B A Darlow; S Dai; G A Gole; G E Quinn; D K Wallace; A Ells; S Carden; L Butler; D Clark; J Elder; C Wilson; S Biswas; A Shafiq; A King; P Brocklehurst; A R Fielder
Journal:  Eye (Lond)       Date:  2017-07-28       Impact factor: 3.775
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.